HUM vs TBPH · P/E 39, rev $117.76B vs P/E 7.5, rev $18.8M
Humana Inc (HUM) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported TBPH revenue for 2024-12-31 was $18.8M. Net income was -$15.5M. Revenue was up 11.2% from 2024-09-30 to 2024-12-31. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the HUM and TBPH stock pages for the full models.
Not investment advice.